InflaRx N.V. (IFRX) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed Veraxa Biotech (VRXA) over the past year, losing 11.9% versus a loss of 90.1%. InflaRx N.V. is the larger company by market cap ($153.3 million vs $147.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | VRXA |
|---|---|---|
| Share price | $1.04 | $1.04 |
| Market cap | $153.26M | $147.06M |
| 1-day change | -4.59% | +0.97% |
| YTD return | +2.97% | -90.25% |
| 1-year return | -11.86% | -90.10% |
| 5-year return | -79.53% | — |
| EPS (TTM) | $-0.37 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.95 | $27.36 |
| 52-week low | $0.798 | $0.90 |
| Distance from 52-week high | -64.73% | -96.20% |
| Analyst consensus | none | — |
| Avg. price target upside | +696.15% | — |
| Average volume | 868.66K | 267.82K |
| Shares outstanding | 147.37M | 141.41M |
| Employees | 65 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed VRXA by 78.2 percentage points over the past year.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Veraxa Biotech
VRXA stock →Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
IFRX vs VRXA FAQ
Which is bigger, InflaRx N.V. or Veraxa Biotech?
InflaRx N.V. (IFRX) is larger, with a market capitalization of $153.26M compared with $147.06M for Veraxa Biotech (VRXA).
Which stock has performed better over the past year, IFRX or VRXA?
IFRX returned -11.86% over the past 12 months, compared with -90.10% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are InflaRx N.V. and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.